Rejuvenation Technologies is extending telomeres using telomerase RNA to treat age-related diseases. Our pipeline includes respiratory, hepatic, and hematopoietic deficiency indications. We recently received over $5M in grants including a $4M grant from the California Institute of Regenerative Medicine (CIRM) to extend telomeres to treat pulmonary fibrosis. Since being launched from Stanford University the founders have developed highly efficient and well-tolerated delivery vehicles for delivering mRNA and circular RNA to extra-hepatic targets. We are on track to begin clinical trials in 2025.